Ann: Two PTX abstracts accepted at prestigious ISCT conference, page-15

@Drian, agreed with post, I think the abstracts are definitely not the silver bullet that some hype them up to be, rather I think that it is a combination of multiple aspects such as recognition by the wider medical community to establish credibility among their peers for the data from clinical trials and background scientific info, investor interest - particularly interest from larger institutions, market forces and the general mood of the share market environment. I am still confident this is a great product, but maintain that prior to reaching impressive heights from a SP perspective, it may be better to be tapped on the shoulder from Big Pharma for a buy out, takeover etc as that time period could be substantially shorter than the former alternative